Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests

Sep 22 2017

• By Brenda Sandburg

Related Content

Trump Exec Order On Drug Costs: Seeking To Balance Access, Innovation

Jun 24 2017

Biosimilars Statistical Guidance Reflects Early Development Approach

Sep 22 2017

FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development

Sep 12 2017

Gene Therapy Platforms May Require Less Preclinical Data, Gottlieb Says

Sep 08 2017

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Sep 21 2017

FDA and Drug Pricing: Lowering The Cost of Capital – Not The Cost Of Drugs

Jul 21 2017

Drug Pricing Pundit Gottlieb Likely To Stay In His Lane At FDA

Apr 14 2017

Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff

May 16 2017

Related Companies

Pfizer Inc.

Johnson & Johnson

Samsung Bioepis Co., Ltd.

Merck & Co., Inc.

Novartis AG

Amgen, Inc.

Amgen, Inc.

Allergan plc

Genentech, Inc.

Novartis AG

Additional Topics

United States Biosimilars Pricing Debate Policy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window